Due to the limited knowledge about the molecular etiology of ovarian cancer, if only the BRCA1/2 gene is tested, more than 5% of patients with deleterious variants in other known risk genes will be missed [10,11]. This evidence concerns the gene BRCA1 and ovarian cancer.